Gossamer Bio GOSS 深 沪
交易中 05-18 11:40:17 美东时间
0.2356
-0.104
-30.71%
华盛通- 最 高0.30
- 今 开0.30
- 成交量 1619.52万股
- 最 低 0.2023
- 昨 收 0.34
- 总市值 5529.44万
- 52周最高 3.87
- 市盈率 静 --
- 换手率 6.90%
- 52周最低 0.2023
- 委 比 -98.55%
- 总股本 2.35亿
- 历史最高 27.15
- 量 比 15.91
- 振 幅 28.74%
- 历史最低 0.2023
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript
Gossamer Bio (NASDAQ:GOSS) held its first-quarter earnings conference call on M...
今天 22:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
今天 20:05
Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase Warrants
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
今天 19:20
Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the
今天 17:53
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial
Gossamer (GOSS) told investors its Phase three PROSERA study was on track, with...
04-23 02:35
Cantor Fitzgerald Downgrades Gossamer Bio to Neutral
Cantor Fitzgerald analyst Olivia Brayer downgrades Gossamer Bio (NASDAQ:GOSS) from Overweight to Neutral.
03-23 17:56
Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss
Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss Levi & Korsinsky is investigating potential claims on behalf of Gossamer shareholders after the company said its Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary 6-minute walk d
03-19 21:02
Small-Cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
03-13 21:55
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
